GLUT-1 as a receptor for HTLV envelopes and its uses
The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linked to an overexpression of GLUT1 on cell surfaces, or the in vitro detection of GLUT1 on cell surfaces. The invention also relates to pharmaceutical compositions containing GLUT1, or fragments or sequences derived thereof, and to their uses such as in the frame of the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV.
1. A method for treating solid tumors overexpressing GLUT1 on cell surfaces, said method comprising administering to a subject in need thereof an effective amount of a GLUT1 binding polypeptide,
wherein,
said GLUT1 binding polypeptide comprises an envelope protein selected from the group consisting of HTLV-1, HTLV-2, STLV-1, STLV-2 or STLV-3, or a fragment thereof, wherein said fragment has an N-terminal located between positions 1 to 90, and a C-terminal located between positions 135 to 245, of the amino acid sequence of said envelope protein, and
said GLUT1 binding polypeptide or fragment thereof specifically binds to the ubiquitous vertebrate glucose transporter GLUT1 of SEQ ID NO: 2.
2. The method according to claim 1 , wherein the solid tumors are selected from the group consisting of brain tumors, squamous cell carcinoma, hypopharyngeal carcinoma, breast cancer, cervical carcinoma, ovarian carcinoma, pancreatic cancer, and insulinoma.
3. The method of claim 1 , wherein the GLUT1 binding polypeptide is able to bind to at least one fragment of GLUT1 selected from the group consisting of:
SEQ ID NO: 25:
NAPQKVIEEFY;
SEQ ID NO: 26:
NQTWVHRYGESILPTTLTTLWS;
SEQ ID NO: 27:
KSFEMLILGR;
SEQ ID NO: 28:
DSIMGNKDL;
SEQ ID NO: 29:
YSTSIFEKAGVQQP;
SEQ ID NO: 30:
EQLPWMSYLS;
SEQ ID NO: 31:
QYVEQLC;
and
SEQ ID NO: 32:
IVGMCFQYVEQLC.
4. The method of claim 3 , wherein the GLUT1 binding polypeptide is able to bind to
SEQ ID NO: 32:
IVGMCFQYVEQLC
5. The method of claim 1 , wherein the GLUT1 binding polypeptide is a fragment of the envelope protein selected from the group consisting of:
an envelope protein of HTLV-1,
an envelope protein of HTLV-2,
an envelope protein of STLV-1,
an envelope protein of STLV-2, and
an envelope protein of STLV-3.
6. The method of claim 5 , wherein the envelope protein is selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, and SEQ ID NO: 12.
7. The method of claim 1 , wherein said fragment has the N-terminal located between positions 75 to 90, and the C-terminal located between positions 135 to 150, of the amino acid sequence of said envelope proteins.
8. The method of claim 1 , wherein the envelope protein sequence is selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, and SEQ ID NO: 12.
9. The method of claim 1 , wherein the envelope protein sequence is SEQ ID NO: 4, and the fragment has the N-terminal located between position 83 to 89, and the C-terminal located between position 139 to 145.
10. The method of claim 1 , wherein the envelope protein sequence is SEQ ID NO: 6, and the fragment has the N-terminal located between position 79 to 85, and the C-terminal located between position 135 to 141.
11. The method of claim 1 , wherein the envelope protein sequence is SEQ ID NO: 8, and the fragment has the N-terminal located between position 83 to 89, and the C-terminal located between position 139 to 145.
12. The method of claim 1 , wherein the envelope protein sequence is SEQ ID NO: 10, and the fragment has the N-terminal located between position 79 to 85, and the C-terminal located between position 135 to 141.
13. The method of claim 1 , wherein the envelope protein sequence is SEQ ID NO: 12, and the fragment has the N-terminal located between position 82 to 88, and the C-terminal located between position 138 to 144.
14. The method according to claim 1 , wherein the solid tumor is breast cancer.
15. The method of claim 1 , wherein said GLUT1 binding polypeptide comprises a fragment of the envelope protein of a human T-cell leukaemia virus (HTLV).
16. The method of claim 1 , wherein said GLUT1 binding polypeptide comprises the polypeptide of SEQ ID NO: 6, or a fragment thereof that specifically binds to the GLUT1 of SEQ ID NO: 2.
17. A method of inhibiting glucose consumption in breast cancer tumor cells in a patient, comprising administering to the patient an effective amount of a GLUT1 binding polypeptide, said GLUT1 binding polypeptide comprising the polypeptide selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, and SEQ ID NO: 12, or a fragment thereof that specifically binds to the GLUT1 of SEQ ID NO: 2.
18. A method of treating breast cancer, comprising administering to a patient in need thereof an effective amount of the polypeptide selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, and SEQ ID NO: 12, or a fragment thereof that specifically binds to the GLUT1 of SEQ ID NO: 2, wherein the effective amount of the polypeptide inhibits glucose consumption of the breast cancer cells.